Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01472939
Recruitment Status : Completed
First Posted : November 17, 2011
Results First Posted : April 15, 2014
Last Update Posted : June 9, 2021
Sponsor:
Information provided by (Responsible Party):
Takeda ( Shire )

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The aim of this study is to establish a dose-related effect of a selective 5-HT4 receptor agonist compared to placebo on residual symptoms (regurgitation with or without heartburn) in subjects with GERD who have persistent symptoms while on PPI therapy.

Condition or disease Intervention/treatment Phase
Gastroesophageal Reflux Disease Drug: SSP-002358 (0.1 mg) + PPI Drug: SSP-002358 (0.5 mg) + PPI Drug: SSP-002358 (2.0 mg) + PPI Drug: Placebo + PPI Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 480 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2b, Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate Efficacy of a Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD) With Persistent Regurgitation With or Without Heartburn
Actual Study Start Date : February 27, 2012
Actual Primary Completion Date : May 14, 2013
Actual Study Completion Date : May 14, 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: GERD Heartburn

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: SSP-002358 (0.1 mg) + Proton Pump Inhibitor (PPI) Drug: SSP-002358 (0.1 mg) + PPI
0.1 mg tablet three times daily (t.i.d.) taken in addition to a PPI
Other Name: SPD557
Active Comparator: SSP-002358 (0.5 mg) + PPI Drug: SSP-002358 (0.5 mg) + PPI
0.5 mg tablet t.i.d. taken in addition to a PPI
Active Comparator: SSP-002358 (2.0 mg) + PPI Drug: SSP-002358 (2.0 mg) + PPI
2.0 mg tablet t.i.d. taken in addition to a PPI
Placebo Comparator: Placebo + PPI Drug: Placebo + PPI
Placebo t.i.d. taken in addition to a PPI


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Change From Baseline in Percent Regurgitation-Free Days Over Weeks 5-8 [ Time Frame: Baseline and over weeks 5-8 ]

Secondary Outcome Measures :
  1. Change From Baseline in Heartburn-Free Days Over Weeks 5-8 [ Time Frame: Baseline and over weeks 5-8 ]
  2. Change From Baseline in the Persistent Reflux Integrated Symptom Measurement (PRISM) Liquid and Food Domain Scores Over Weeks 5-8 [ Time Frame: Baseline and over weeks 5-8 ]
    PRISM is a 21 item patient-reported outcome instrument with 4 domains. Items are scored using various scales. Total score ranges from 0-100. Higher scores indicate more severe or frequent symptoms.

  3. Area Under the Steady-state Plasma Concentration-time Curve (AUC) of SSP-002358 [ Time Frame: Over 8 hours post-dose (week 2 or later) ]
    Area under the plasma concentration versus time curve can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.

  4. Steady State Maximum Plasma Concentration (Cmax) of SSP-002358 [ Time Frame: Over 8 hours post-dose (week 2 or later) ]
    Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administered.

  5. Time to Maximum Plasma Concentration (Tmax) of SSP-002358 [ Time Frame: Over 8 hours post-dose (week 2 or later) ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Written Informed Consent Form signed voluntarily before the first study-related activity.
  2. Aged between 18 and 70 years, inclusive.
  3. Subjects with a history of the cardinal symptoms of GERD (both heartburn and regurgitation) prior to PPI therapy.
  4. Subjects with symptoms of GERD for at least 6 months prior to the Screening Visit.
  5. Subjects who have persistent symptoms of regurgitation for 3 or more days over the past week with or without heartburn while on PPI.
  6. Subjects have at least some improvement to the symptom of heartburn while on PPI therapy.
  7. Subjects on PPI therapy for at least 8 weeks prior to the Screening Visit of which the last 4 weeks are on a stable labeled dose for any GERD indication according to the country label, where a change of PPI therapy would not impact the symptoms (twice-daily dosing of PPI is not allowed in the last 4 weeks)

Exclusion Criteria:

  1. Subjects who show no response to heartburn while on PPI therapy.
  2. Subjects with dyspepsia symptoms that are more predominant than their GERD symptoms (heartburn and/or regurgitation).
  3. Subjects with prior endoscopic anti-reflux procedure or major GI surgery or subjects with major GI disorders.
  4. Presence of severe and clinically uncontrolled cardiovascular, liver, lung or neurologic disease, cancer or AIDS.
  5. Alarm symptoms suggestive of malignancies or organic disease.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01472939


Locations
Show Show 88 study locations
Sponsors and Collaborators
Shire
Investigators
Layout table for investigator information
Study Director: Study Director Takeda
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Shire
ClinicalTrials.gov Identifier: NCT01472939    
Other Study ID Numbers: SPD557-206
2011-004388-62 ( EudraCT Number )
First Posted: November 17, 2011    Key Record Dates
Results First Posted: April 15, 2014
Last Update Posted: June 9, 2021
Last Verified: May 2021
Additional relevant MeSH terms:
Layout table for MeSH terms
Gastroesophageal Reflux
Esophagitis, Peptic
Esophageal Motility Disorders
Deglutition Disorders
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases
 Esophagitis
Gastroenteritis
Peptic Ulcer
Duodenal Diseases
Intestinal Diseases
Stomach Diseases